Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 12, 2021 11:17am
150 Views
Post# 32275867

RE:RE:RE:Best Option?

RE:RE:RE:Best Option? Unfortunately, I think Sabbocat is right. This is a standard Canadian bought deal. One broker I know said his firm got a 20% allocation of the deal and that 15% of that was given to the retail side. He asked for more shares than he got so it appeared oversubscribed on the retail side. But the idea that a big institutional investor is involved seems highly unlikely. 

Wino115 wrote: Baker manages $24bil, so this is super tiny for them.  One of their biggest holdings, though, is Seatle Genetics (SeaGen now).  We know that is very similar to what they are doing with SORT1 platform, so they clearly have knowledge in that area. It just seems way to small for them though but I'd love to be wrong on that. If it was the full 20% stake, there wouldn't be any reason for a broker to be involved or to pay a high fee to them though. It would be THTX bringing the client to them, not the other way around. 


SPCEO1 wrote: Paul actually made that comment on one of the broker calls in the Fall and it gave me confidence that they would not do a deal that was foolish since they apparently had a number of good options. Right now, based on what is public, this deal seems to indicate they had very few options and had to grasp the money they could before the stock market bubble burst.

I am hoping the opposite is actually true but we only have hope until more details, if there are any, are released.

I hope that we have a super impressive, medically savvy, historically very successful long term investor that took a 20% stake in the company via this deal. There is a investment fund called the Baker Brothers that fit that description but I am sure there are others as well. If such a firm did a lot of due diligence as our CEO has already said some have done on the cancer program (see JFM1330's reminder of that) and negotiated a this sweetheart deal to take a big stake in TH, then there will be considerable positives flowing from that. One is a lot of copycat investors buying THTX's stock in the open market because they want to do whatever the Baker Brothers are doing. Second, the Baker Brothers would tell the analysts to pick up coverage of THTX and they would do so in a heartbeat because the Baker Brothers are such a big client. So, a firm like the Baker Brothers no doubt approaches a firm like TH with that value proposition and firms like TH see the logic and go for it. Which is why firms like the Baker Brothers are so successful.

But with no new info along these lines so far, all we have at the moment is a highly dilutive deal, done at a bad time with no new analysts brought on board and therefore it destroys the credibility the company had. I suspect we will see the exact opposite of this once we get all the details but for now, I can see what the market is looking at it that way.
longterm56 wrote:
One of the reports from SPCEO talking to the CEO awhile back said that Paul said "we have alot of options for raising cash. " So we have to choose one of the following: 1) they didn't choose the best option and therefore made a bad decision. 2) they were compelled to make this deal to move forward 3) this was the best option Since #2 is really the same as #3 there are really only two choices. I have to go with #3 realizing that I don't know all the details.

 




<< Previous
Bullboard Posts
Next >>